WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Pharmaphorum Media Limited | November 22, 2018
Indivior has suffered a critical defeat in the US courts for opioid addiction product Suboxone Film, opening the door to generic competition and sparking a run on its shares. The UK company’s attempt to block a generic version of Suboxone Film (sublingual buprenorphine/naloxone) developed by India’s Dr. Reddy’s Laboratories has been rejected by an appeals court, upholding an earlier ruling of non-infringement of a key patent on the brand.Dr. Reddy’s said in a statem...
fiercepharma | July 11, 2019
With the feds sniffing around Indiviors aggressive marketing of its opioid addiction treatment Suboxone, the forecast looked bleak for the drugmaker. The stink was bad enough that Indivior’s former parent company is paying a steep price to clear its name—to the tune of $1.4 billion. Reckitt Benckiser settled with the Justice Department and Federal Trade Commission for $1.4 billion Thursday to end multiple federal probes into an alleged scheme to push sales of the opioid addiction tre...
Indivior | November 21, 2022
Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been unanimously approved by the boards of di...
Business Insights, PHARMA TECH
Indivior | March 06, 2023
Indivior PLC, a global pharmaceutical company, recently announced its successful acquisition of Opiant Pharmaceuticals, Inc. The acquisition strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets. In particular, OPNT003, an investigational opioid overdose treatment, aims to provide an effective treatment option to address the current wave of opioid overdose caused by powerful synthetic opioids such as fentanyl.
Views and Analysis
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE